- Stocks
- Healthcare
- NASDAQ: OMGA

Price (delayed)

$4.11

Market cap

$226.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.08

Enterprise value

$275.73M

The revenue has soared by 92% year-on-year and by 9% since the previous quarter

The company's gross profit has surged by 92% YoY and by 9% QoQ

The EPS has plunged by 82% YoY but it has grown by 6% from the previous quarter

The net income has declined by 17% year-on-year but it is up by 3.2% since the previous quarter

Omega Therapeutics's quick ratio has plunged by 67% YoY

The equity has declined by 43% year-on-year and by 21% since the previous quarter

What are the main financial stats of OMGA

Market
Valuations
Earnings

Shares outstanding

55.14M

Market cap

$226.63M

Enterprise value

$275.73M

Price to earnings (P/E)

N/A

Price to book (P/B)

2.98

Price to sales (P/S)

79.77

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

97.05

Revenue

$2.84M

EBIT

-$110.61M

EBITDA

-$104.31M

Free cash flow

-$100.71M

Per share
Balance sheet
Liquidity

EPS

-$2.08

Free cash flow per share

-$1.83

Book value per share

$1.38

Revenue per share

$0.05

TBVPS

$3.95

Total assets

$217.81M

Total liabilities

$141.77M

Debt

$131.2M

Equity

$76.04M

Working capital

$75.08M

Debt to equity

1.73

Current ratio

3.8

Quick ratio

3.36

Net debt/EBITDA

-0.47

Margins
Efficiency
Dividend

EBITDA margin

-3,671.5%

Gross margin

100%

Net margin

-3,802.9%

Operating margin

-3,890.5%

Return on assets

-57.7%

Return on equity

-107.8%

Return on invested capital

-76.4%

Return on capital employed

-57.9%

Return on sales

-3,893.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Omega Therapeutics stock price performed over time

Intraday

0.74%

1 week

14.64%

1 month

-3.97%

1 year

-36.38%

YTD

36.54%

QTD

36.54%

How have Omega Therapeutics's revenue and profit performed over time

Revenue

$2.84M

Gross profit

$2.84M

Operating income

-$110.53M

Net income

-$108.04M

Gross margin

100%

Net margin

-3,802.9%

The revenue has soared by 92% year-on-year and by 9% since the previous quarter

The company's gross profit has surged by 92% YoY and by 9% QoQ

The net margin has grown by 39% year-on-year and by 11% since the previous quarter

The company's operating margin rose by 38% YoY and by 11% QoQ

What is Omega Therapeutics's growth rate over time

What is Omega Therapeutics stock price valuation

P/E

N/A

P/B

2.98

P/S

79.77

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

97.05

The EPS has plunged by 82% YoY but it has grown by 6% from the previous quarter

The equity has declined by 43% year-on-year and by 21% since the previous quarter

The stock's price to book (P/B) is 23% more than its last 4 quarters average of 2.4

The revenue has soared by 92% year-on-year and by 9% since the previous quarter

The price to sales (P/S) is 25% less than the last 4 quarters average of 105.9

How efficient is Omega Therapeutics business performance

OMGA's ROE has plunged by 96% YoY and by 11% from the previous quarter

The ROS has grown by 38% YoY and by 11% from the previous quarter

OMGA's return on assets is down by 27% year-on-year but it is up by 9% since the previous quarter

The ROIC has grown by 26% from the previous quarter and by 20% YoY

What is OMGA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for OMGA.

How did Omega Therapeutics financials performed over time

The total assets is 54% greater than the total liabilities

Omega Therapeutics's quick ratio has plunged by 67% YoY

Omega Therapeutics's current ratio has plunged by 65% YoY but it has increased by 2.4% from the previous quarter

The debt is 73% greater than the equity

The equity has declined by 43% year-on-year and by 21% since the previous quarter

OMGA's debt to equity is up by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.